Video

Identifying 3 major risk factors for AMD

Author(s):

OT Staff Reports

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Joshua Mali, MD, president of the Macular Degeneration Association, vitreoretinal surgeon at The Eye Associates (Sarasota, FL), discusses the three major risk factors for developing age-related macular degeneration (AMD).


See more AMD Awareness content here, here, and here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
Related Content
Kiora Pharmaceuticals Secures US Patent for KIO-104
July 24th 2025

Kiora Pharmaceuticals Secures US Patent for KIO-104

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Researchers explore ChatGPT4o's ability to generate realistic retinal fundus images
July 22nd 2025

Researchers explore ChatGPT4o's ability to generate realistic retinal fundus images

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

Harrow enters into agreement with Samsung Bioepis for commercial rights to its ophthalmology biosimilar portfolio
July 17th 2025

Harrow enters into agreement with Samsung Bioepis for commercial rights to its ophthalmology biosimilar portfolio

AAVantgarde Bio receives IND clearance for AAVB-039
July 17th 2025

AAVantgarde Bio receives IND clearance for AAVB-039

© 2025 MJH Life Sciences

All rights reserved.